Platforms - Bridging the gap between construction + manufacturing
Read more about our.
“Everybody right now, if you're an architect or a builder, you should be working on your foundational skills with the baseline, anchor, portfolio products,” she says.. It’s then what she calls the “connective tissue” technology, the tech which forms between those products to connect them to other products, which will be the key to getting from “conceptualisation, design, to make, to operate,” she says.. Productization: building a raft in the ocean of construction.The process of productising the pieces and parts involved in construction will help inform our understanding of what technological connective tissue is missing, as well as what we need to do to fill in the gaps.. Amy Marks compares the productisation of those elements to building a raft or reef in the middle of the ocean.
Whether it be a generator, a panel, a bathroom pod, or something else, productisation will provide something solid to work with inside a sea of fluidity, something we can “actually track through and map…”.The key, she says, is that the products must be fully defined.We must understand every aspect, including workflows, performance, and sustainability.
Further, it’s important to recognise that productisation won’t solve everything.However, it will give us a starting point.. Marks refers to this as “chaos to order theory,” a phrase she coined after a superintendent on one of her first jobs described his positive experience working with bathroom pods.
The pods created a welcome amount of certainty and consistency in his day.
He could count on receiving them, he knew exactly what they were, and he could schedule his other work around them.The influence of the R&D led industry is hugely significant, providing the worked through case-studies and directly influencing their supply chain, including contract manufacturers.. Over the course of the discussion, there was a radical switch in the reflections on regulations and regulators.
At the outset, regulators were seen as one of the significant barriers to moving forward at speed.There was some evidence for this as changing a drug registration can take three years and has a significant cost attached to it.
However, it is unclear how many registrations do more than specify a solvent and list suppliers.If so, a change in source hypothetically is a small change.